Idelalisib + Rituximab Successful in Frontline with Some Toxicity

Susan M. O’Brien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some ... Author: ASHReport Added: 12/10/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts